Use of oxidized low-density lipoprotein receptor 1 (OLR1) gene or expressed protein as target in preparation of drug for treating colorectal cancer, where drug can inhibit expression of OLR1 gene or inhibit function of OLR1 protein, to inhibit progression of colorectal cancer